Statement from FDA on continuing efforts to maintain its strong oversight of generic drugs
date:Feb 25, 2019
rough public comment and a constructive dialogue with all partners and stakeholders, including the press. We welcome the scrutiny of our programs. We welcome the accountability inspired by a free press. This dialogue is part of how we advance our public health mission. We also welcome here, the opportunity to lay out our case for our high confidence in our generic program.

To address recent questions raised about the scope and effectiveness of our oversight of generic manufacturing, weve asked

06/17 01:56